Sanara MedTech Inc.
Close on Oct 19, 2026
- Market cap
- $287.08M
- P/E (TTM)
- –
- Dividend yield
- –
About Sanara MedTech
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Sanara MedTech Inc. is a medical technology company that develops and commercializes surgical solutions focused on tissue repair and bone fusion. Operating through a single reportable segment, the company provides products for sterile operating room environments. Its soft tissue offerings include CellerateRX Surgical, a hydrolyzed collagen used to manage surgical wounds, and BIASURGE, a surgical wound irrigation solution. It also supplies bone fusion and orthobiologic products, such as BiFORM bioactive moldable matrix and ALLOCYTE Plus cellular bone matrix. The company primarily sells its products to surgeons, hospitals, and ambulatory surgical centers.
The company is headquartered in Fort Worth, Texas. It conducts its business operations across the United States, targeting surgical facilities and specialty surgeons nationwide. The company has secured product contracts with more than 4,000 hospitals.
Summary of the business section of Sanara MedTech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sanara MedTech Inc.
- Headquarters
- Fort Worth, TX
- Address
- 1200 Summit Ave, Suite 414 76102
- Phone
- (817) 529-2300
- Employees
- 108, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- Weaver and Tidwell, L.L.P., Austin, Texas
Stock & identifiers
- Ticker
- SMTI
- Exchange
- Nasdaq
- IPO date
- Apr 7, 1994
- Shares outstanding
- 9M, Aug 7, 2026
- Public float
- $147.51M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-100 reverse, May 20, 2019; 1-for-100 reverse, May 10, 2019; 1-for-100 reverse, Jun 26, 2002
- SEC CIK
- 714256
- CUSIP
- 79957L100
- ISIN
- US79957L1008
- EIN
- 59-2220004
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Seth D. Yon | Chief Executive Officer, Director | 105,885 |
| Ashley M. Mackey | Controller | 4,967 |
| Jacob A. Waldrop | Chief Operating Officer | 24,377 |
| Elizabeth B. Taylor | Chief Financial Officer | 17,632 |
| Michael D. McNeil | Ch. Acct. & Ch. Admin. Officer | 28,587 |
| Suresh V. Muppalla | Pres & CEO, Tissue Health Plus | 2,973 |
| Robert Andrew DeSutter | Director | 28,740 |
| Roszell Mack III | Director | 21,842 |
| Eric D. Major | Director | 14,232 |
| Keith G. Myers | Director | 9,325 |
| Eric D. Tanzberger | Director | 22,966 |
| Ronald T. Nixon | Director | 1,032,052 |
| Ann Beal Salamone | Director | 26,858 |
| Sara N. Ortwein | Director | 25,415 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Former PEO | $585.48K | $450.15K | $740.24K | $51 | – |
| FY2025 Peo | $2.31M | $1.52M | $740.24K | $51 | – |
| FY2024 Former PEO | $1.69M | $1.17M | $523.74K | $112 | – |
| FY2024 Non Peo Neo | $523.74K | $455.02K | $523.74K | $112 | – |
| FY2024 Peo | $855.76K | $876.63K | $523.74K | $112 | – |
| FY2023 Former PEO | $909.65K | $784.31K | $707.88K | $82 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had a staff of 108 full-time employees.”
Corporate history
Events identified from SEC filings